Get to know our clinical trials

Phase II, multicenter, unblinded, randomized, multicenter clinical trial of venetoclax and azacitidine plus cusatuzumab compared with venetoclax and azacitidine alone in patients with newly diagnosed AML who are ineligible for intensive therapy.

Imagen de la Dra. Ana Alfonso Piérola, especialista en Hematología de la Clínica Universidad de Navarra. La Dra. Alfonso se dedica al estudio y tratamiento de los síndromes mielodisplásicos y las leucemias mieloblásticas agudas.
Dr. Ana Alfonso Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • PHASE II, MULTICENTER, UNBLINDED, RANDOMIZED, MULTICENTER STUDY OF VENETOCLAX AND AZACITIDINE PLUS CUSATUZUMAB COMPARED TO VENETOCLAX AND AZACITIDINE ALONE IN PATIENTS WITH NEWLY DIAGNOSED AML WHO ARE NOT ELIGIBLE FOR INTENSIVE THERAPY.
  • Code EudraCT: 2024-510991-19-00
  • Protocol number: OV-AML-1231
  • Promoter: Onyx Therapeutics, Inc.
  • Molecule/Drug: Cusatuzumab
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION